Corbus says Phase 1b CANYON-1 obesity trial of CRB-913 reaches last patient last visit
Reuters2026/08/04 12:33- Corbus reached last patient last visit in its Phase 1b CANYON-1 trial of obesity drug CRB-913.
- Topline results were not presented yet; data are expected in September 2026.
- Study aims to show whether the once-daily oral therapy can support meaningful weight loss with tolerability suited for longer-term use.
- Management positioned CRB-913 as a non-incretin alternative for patients who stop GLP-1 treatments due to side effects or limited benefit.
- Company also highlighted preclinical findings suggesting lower brain exposure versus monlunabant, a potential differentiator for safety positioning.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y
As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.
Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260
Crypto prices
More
